

CURRICULUM VITAE

CHARLES S. WILCOX, Ph.D., M.P.A., M.B.A.**Praxis Research Consulting**

Work Address:

1400 Quail Street
Suite 285
Newport Beach, CA 92660

(949) 877-6103

EDUCATION

- 1978 B.S. University of Southern California
Public Affairs/Administration, With Honors
- 1979 M.P.A. University of Southern California
Emphasis in Systems Analysis and
Manpower Management/Personnel Administration
- 1982 M.B.A. University of Southern California
Emphasis in Marketing, Marketing Research and
Consulting Services (Certification/Completion in 1992)
- 1989 Ph.D. University of Southern California
Four areas of specialization/qualification:
1) Applied Behavioral Sciences, 2) Research,
3) Administrative Theory, 4) Organizational Behavior
Dissertation: Questions of and by Questionnaires...

EXPERIENCE

- 2019-Present Praxis Research Consulting
Newport Beach, California
Chief Executive Officer
- Currently serving on Board(s) of Directors for both private (i.e., for profit) and public (i.e., non-profit 501c3) organizations, including scientific advisory boards. Consultative roles encompass a wide array of clinical research, marketing research and personnel management. Clients have included public and private corporations, as well as universities and V.A. hospitals.
- 1984-2019 Pharmacology Research Institute
Los Alamitos/Newport Beach/Encino, California
Executive Director/Owner/Founder

Responsibilities include the solicitation and negotiation of all grant funding for the Institute. In addition to the overall conduct (and sometimes design) of clinical investigations, operational duties include: planning, staffing, budgeting, patient recruitment, fulfillment of and compliance with U.S. and foreign regulatory requirements as well as the dissemination (i.e., publication and presentation) of results. Clinical responsibilities include preliminary pre-screening of patients, global ratings (i.e., A.D.A.S.-Cog C.G.I.C., C.D.R. and C.I.B.I.C.-Plus, etc.), medication accountability and assistance with informed consent processes.

1981-1984

Psychopharmacology Research Associates, Inc.
Executive Director

Co-founder of this California non-profit (501 c 3) corporation. Directly responsible for the procurement of grants, gifts, and donations. Administrative duties included technical and professional staffing as well as the establishment and maintenance of collaborative relationships with public and private institutions.

1979-1981

Psychopharmacology Unit
University of California, Irvine (affiliate)
Administrative Analyst

Primary responsibilities included the logistical planning, staffing, and budgeting of clinical research investigations. Also responsible for the organization's compliance with updated/revised rules and guidelines set forth by the Food and Drug Administration (FDA). Additional tasks included representation of the research unit at both governmental and corporate audits.

1978-1979

Psychopharmacology Research Unit
University of California, Irvine (affiliate)
Research Administrator

Responsible for the quality and timely conduct of clinical investigations of new chemical entities; majority of duties related to the quality of data collection forms prior to submission of the data to sponsors/FDA. Advised in the recruitment and selection of administrative and clerical personnel.

1978

State of California, Governor's Office,
Office of Planning and Research,
Sacramento, California
Assistant Policy Analyst

Assistant (part-time) to Dr. Carl Werthman at U.S.C., performed analytical studies on proposed government policies; reported criticisms and recommendations for future state planning and reference.

1977

The American Petroleum Institute
Washington, D.C.
Legislative Analyst

Initially a traditional/part-time internship, responsibilities included attendance at and the reporting of United States Senate and House Committee meeting proceedings for dissemination to sponsors and affiliates of the Institute. Duties ultimately expanded to include the briefing of industry representatives in preparation for Congressional Committee testimony.

- 1976 Joint Educational Project
University of Southern California
Spanish/English Tutor
- Responsibilities included developing and implementing teaching methodologies to assist Spanish-speaking students in acquiring fundamental English verbal skills.

CONSULTANCIES (Partial)

- 2020-Present Syneos Health Site Advocacy Group (SAG) for Protocol Optimization
Society for Clinical Research Sites (SCRS)
- 2016-2019 Alzheimer’s Orange County Medical and Scientific Advisory Board
- 2015-2019 INC Research Site Advocacy Group (SAG) for Protocol Optimization
Society for Clinical Research Sites (SCRS)

RELATED VOLUNTEER WORK

American Society of Clinical Psychopharmacology
ASCP Industry Advisory Council Member
Term: 06/01/2022 - 05/31/2026

Alzheimer’s Association, Orange County Chapter
Board of Directors

Alzheimer's Los Angeles Speakers Bureau
4221 Wilshire Blvd. Suite 400
Los Angeles, California 90010
and

Alzheimer’s Orange County Speakers Bureau
2515 Mc Cabe Way, #200
Irvine, California 92614

The STARR Coalition Diversity Workgroup

AIM: Alzheimer’s Impact Movement – Leadership and Advocacy Council

ORGANIZATIONS

American Headache Society
Drug Information Association
Society for Clinical Research Sites
Pi Alpha Alpha National Honor Society
Regulatory Affairs Professionals Society
American Federation of Medical Research
Society for Research on Nicotine and Tobacco
European College of Neuropsychopharmacology
American Society of Clinical Psychopharmacology
American Society of Public Administration (Life Member)
International Society for CNS Clinical Trials and Methodology
American Professional Society of ADHD and Related Disorders
International Society to Advance Alzheimer's Research and Treatment
Association of Clinical Research Professionals (C.C.R.C. Certified 1992)

PUBLICATIONS

1. Cohn, J.B. and Wilcox, C.S. Dangerousness as a standard for civil commitment. *American Journal of Forensic Psychiatry* 1(4): 169-174, 1983.
2. Cohn, J.B. and Wilcox, C.S. Long-term comparison of alprazolam, lorazepam and placebo in patients with an anxiety disorder. *Pharmacotherapy* 4(2): 93-98, 1984.
3. Cohn, J.B.; Wilcox, C.S. and Cohn, J. Treatment of the anxious elderly patient. *Geriatric Medicine Today* 3(12): 45-55, 1984.
4. Cohn, J.B. and Wilcox, C.S. Comparison of fluoxetine, imipramine and placebo in patients with major depressive disorder. *Journal of Clinical Psychiatry* 46(3): 26-31, 1985.
5. Cohn, J.B. and Wilcox, C.S. Praxilene in the treatment of senile dementia. In: *Conservative Therapy of Arterial Occlusive Disease*, G. Trubestein (ed.), Georg Thieme Verlag Stuttgart, New York, 1986, pp. 330-333.
6. Cohn, J.B.; Wilcox, C.S. and Meltzer, H.Y. Neuroendocrine effects of buspirone in patients with generalized anxiety disorder. *American Journal of Medicine* 80 (suppl. 3B): 36-40, March 1986.
7. Cohn, J.B. and Wilcox, C.S. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study. *Journal of Clinical Psychiatry* 47(8): 409-412, August 1986.
8. Cohn, J.B. and Wilcox, C.S. Buspirone: effectiveness, safety and mechanisms of action. *IM-Internal Medicine for the Specialist* 8(1): 216-224, January 1987.

9. Cohn, J.B. and Wilcox, C.S. Diagnostic criteria for Alzheimer's disease: an evaluation. *Geriatric Medicine Today* 6(61): 77-88, June 1987.
10. Cohn, J.B.; Pyke, R.E. and Wilcox, C.S. Adinazolam mesylate and placebo in depressed outpatients: a 6-week double-blind comparison. *Journal of Clinical Psychiatry* 49(4): 142-147, 1988.
11. Cohn, J.B.; Pyke, R.E. and Wilcox, C.S. Adinazolam mesylate and placebo in depressed outpatients. *Psychiatry Digest*, pp. 13-14, December 1988.
12. Cohn, J.B. and Wilcox, C.S. Baixo Potencial de Sedacao da Buspirona Comparado com Alprazolam e Lorazepam no Tratamento de Pacientes com Anxiedade: Um Estado Duplo-Cego. *Revista Brasileira de Medicina* Vol. 46, Nos. 1/2, Jan/Feb, 1989.
13. Crowder, J.E.; Cohn, J.B.; Savitsky, J.P.; Morgan, D.L.; Slywka, J.; Cobert, B.L.; Hryniewicki, S.W.; Piccirillo, R.T.; and Wilcox, C.S. Efficacy and safety of pentoxifylline in geriatric patients with intermittent claudication. *Angiology: the Journal of Vascular Diseases* 40(9): 795-802, September 1989.
14. Wilcox, C.S.; Cohn, J.B.; Crowder, J.E. and Ryan, P.J. Patient Motivation and Placebo Response. *Journal of Clinical Research and Pharmacoeconomics* 4(2): 154, June 1990.
15. Cohn, J.B.; Crowder, J.E.; Wilcox, C.S. and Ryan, P.J. A placebo- and imipramine-controlled study of paroxetine. *Psychopharmacology Bulletin* 26(2): 185-189, 1990.
16. Cohn, J.B.; Wilcox, C.S.; Bremner, J. and Ettinger, M. Hypnotic efficacy of estazolam compared with flurazepam in outpatients with insomnia. *Journal of Clinical Pharmacology* 31(8): 747-750, August 1991.
17. Cohn, J.B.; Wilcox, C.S. and Lerer, B.E. Development of an 'Early' Detection Battery for Dementia of the Alzheimer Type. *Progress in Neuro-psychopharmacology & Biological Psychiatry* 15: 433-479, 1991.
18. Cohn, J.B.; Wilcox, C.S.; Bowden, C.L.; Fisher, J.G. and Rodos, J.J. Double-blind comparison of buspirone and clorazepate in anxious outpatients with and without depressive symptoms. *Psychopathology* 25(S1): 10-21, 1992.
19. Cohn, J.B. and Wilcox, C.S. Paroxetine in Major Depression: A double-blind trial with imipramine and placebo. *Journal of Clinical Psychiatry* 53:2(suppl): 52-56, February 1992.
20. Wilcox, C.S.; Cohn, J.B.; Linden, R.D.; Heiser, J.F.; Lucas, P.B.; Morgan, D.L. and DeFrancisco, D. Predictors of Placebo Response: A retrospective analysis. *Psychopharmacology Bulletin* 28(2): 157-162, 1992.
21. Cohn, J.B.; Wilcox, C.S. and Morrissey, J.L. Differentiating Delirium from Dementia. *American Journal of Forensic Psychiatry* 13(4): 3-25, 1992.

22. Gammans, R.E.; Stringfellow, J.C.; Hvizdos, A.J.; Seidehamel, R.J.; Cohn, J.B.; Wilcox, C.S.; Fabre, L.F.; Pecknold, J.C.; Smith, W.T. and Rickels, K. Use of Buspirone in Patients with Generalized Anxiety Disorder and Coexisting Depressive Symptoms: A Meta-Analysis of Eight Randomized, Controlled Studies. *Neuropsychobiology* 25: 193-201, 1992.
23. Cohn, J.B.; Wilcox, C.S. and Goodman, L.I. Antidepressant Efficacy and Cardiac Safety of Trimipramine in Patients with Mild Heart Disease. *Clinical Therapeutics* 15 (No.1): 114-126, 1993.
24. Wilcox, C.S.; Ryan, P.J.; Morrissey, J.L.; Cohn, J.B.; De Francisco, D.F.; Linden, R.D. and Heiser, J.F. A Fixed-Dose Study of Adinazolam-SR Tablets in Generalized Anxiety Disorder. *Prog. Neuro-Psychopharmacol. & Biol. Psychiat* 18: 979-993, 1994.
25. Linden, R.D.; Wilcox, C.S.; Heiser, J.F.; Cavanaugh, E. and Wisselink, P.G. Are Selective Serotonin Re-uptake Inhibitors Well Tolerated in Somatizing Depressives? *Psychopharmacology Bulletin*, 30(2): 151-156, 1994.
26. Heiser, J.F. and Wilcox, C.S. "Book Review" Human Psychopharmacology—Measures and Methods, Volume 4, I. Hindmarch and P.D. Stonier (editors), *The Annals of Pharmacotherapy* 28: 1205, October 1994.
27. Wilcox, C.S.; Cohn, J.B.; Katz, B.B.; Mijares, C.P.; Guarino, J.J.; Panagides, J. and DeFrancisco, D. A Double-Blind, Placebo-Controlled Study Comparing Mianserin and Amitriptyline in Moderately Depressed Outpatients. *International Clinical Psychopharmacology* 9: 271-279, Winter 1994.
28. Wilcox, C.S.; Heiser, J.F.; Crowder, A.M.; Wassom, N.J.; Katz, B.B. and Dale, J.L. Comparison of the Effects on Pupil Size and Accommodation of Three Regimens of Topical Dapiprazole. *British Journal of Ophthalmology* 79(6): 544-548, June 1995.
29. Adams, J.B.; Pyke, R.E.; Costa, J.; Cutler, N.R.; Schweizer, E.; Wilcox, C.S.; Wisselink, P.G.; Greiner, M; Pierce, M.W. and Pande, A.C. A Double-blind, Placebo-Controlled Study of a CCK-B Receptor Antagonist, CI-988, In Patients with Generalized Anxiety Disorder. *The Journal of Clinical Psychopharmacology* 15(6): 428-434, December 1995.
30. Feiger, A.; Kiev, A.; Shrivastava, R.K.; Wisselink, P.G. and Wilcox, C.S. Nefazodone Versus Sertraline in Outpatients with Major Depression: Focus on Efficacy, Tolerability, and Effects on Sexual Function and Satisfaction. *Journal of Clinical Psychiatry* (57): January 1996.
31. Wilcox, C.S.; Katz, B.B.; Morgan, D.L.; Morrissey, J.L.; Schneider, A.L. and DeFrancisco, D.F. Increasing Ethnic Diversity and Managed Care: How Will They Influence Research Patient Recruitment in the 1990s? *Psychopharmacology Bulletin* 32(2): 193-200, 1996.
32. Walczak, D.D.; Apter, J.T.; Halikas, J.A.; Borison, R.L.; Carman, J.S.; Post, G.L.; Patrick, R.; Cohn, J.B.; Cunningham, L.A.; Rittberg, B.; Preskorn, S.H.; Kang, J.S. and Wilcox, C.S. The Oral Dose-Effect Relationship for Fluvoxamine: A Fixed-Dose Comparison Against Placebo in Depressed Outpatients. *Annals of Clinical Psychiatry* 8(3): 139-151, September 1996.

33. Wilcox, C.S.; Ferguson, J.M.; Dale, J.L. and Heiser, J.F. A Double-Blind Trial of a Low Dose Range and High Dose Range of Gepirone-ER Compared to Placebo in the Treatment of Depressed Outpatients. *Psychopharmacology Bulletin* 32(3): 335-342, 1996.
34. Lahmeyer, H.; Wilcox, C.; Kann, J. and Leppik, I. Subjective Efficacy of Zolpidem in Outpatients with Chronic Insomnia. *Clinical Drug Investigation* 12(3): 134-144, March 1997.
35. Schneider, A.L. and Wilcox, C.S. Combined Therapies in the Treatment of Rapid Cycling Lithium Resistant Mania in Geriatric Patients. *Journal of Affective Disorders* 47: 201-205, 1998.
36. Heiser, J.F. and Wilcox, C.S. 5HT_{1A} Receptor Agonists as Antidepressants: Pharmacological Rationale and Evidence for Efficacy. *CNS Drugs* 10(5): 343-353, November 1998.
37. Feiger, A.D.; Bielski, R.J.; Bremner, J.; Heiser, J.F.; Trivedi, M.; Wilcox, C.S.; Roberts D.L.; Kensler, T.T.; McQuade, R.D.; Kaplita, S.B. and Archibald, D.G. Double-Blind, Placebo-Substitution Study of Nefazodone in the Prevention of Relapse During Continuation Treatment of Outpatients with Major Depression. *International Clinical Psychopharmacology* 1999, 14: 19-28.
38. Grosz, D.E.; Morrissey, J.L. and Wilcox, C.S. Comparative Effectiveness of Triptans for the Treatment of Migraine. *Today's Therapeutic Trends* 20(2): 97-112, 2002.
39. Wilcox, C.S.; Linden, R.D.; D'Amico, M.F.; DeFrancisco, D.F.; Morrissey, J.L. and Heiser, J.F. Nefazodone in the Treatment of Elderly Patients with Depression. *Today's Therapeutic Trends* 20(2): 183-196, 2002.
40. Thase, M.E.; Ferguson, J.M.; Lydiard, R.B. and Wilcox, C.S. Citalopram Treatment of Paroxetine-Intolerant Depressed Patients. *Depression and Anxiety* 16: 128-133, 2002.
41. Oskooilar, N.; Wilcox, C.S.; Tong, M. and Grosz, D.E. Body Mass Index and Response to Antidepressants in Depressed Research Subjects. *Journal of Clinical Psychiatry* 70:11, 1609-1610, November 2009.
42. Wilcox, C.S.; Oskooilar, N.; Erickson, J.S.; Billes, S.K.; Katz, B.B.; Tollefson, G. and Dunayevich, E. An Open-Label Study of Naltrexone and Bupropion Combination Therapy for Smoking Cessation in Overweight and Obese Subjects. *Addictive Behaviors* 25: 229-234, 2010.
43. Wilcox, C.S.; Noble E.P. and Oskooilar, N. ANKK1/DRD2 Locus Variants Are Associated With Rimonabant Efficacy in Aiding Smoking Cessation: Pilot Data. *Journal of Investigative Medicine* 59(8) 1280-1283, December 2011.
44. Shiovitz, T.M.; Wilcox, C.S.; Gevorgyan, L. and Shawkat, A. CNS Sites Cooperate to Detect Duplicate Subjects with a Clinical Trial Subject Registry. *Innovations in Clinical Neuroscience* 10(2); 17-21, February 2013.

45. Wilcox, C.S.; Franceschi, L. and Simmons, A. Layperson/Plain Language Summaries: Can Sponsors, CROs, and Sites Deliver in 2020? *Innovations in Clinical Neuroscience* 2020;17(7-9) 9-13.
46. Wilcox, C.S. “Supreme Change” is Needed, *PA Times*, American Society for Public Administration. PATIMES.ORG, October 22, 2020.
47. Wilcox, C.S. Diversity, Equity and Inclusion: Alzheimer’s and Dementia Research-Related Global Challenges, Solutions and Opportunities, *Innovations in Clinical Neuroscience*, Fall [October-December 2021] Vol. 18, No. 10-11, Supplement 1, pg. S-11.
48. Wilcox, C.S. Alzheimer’s #115: A global 3-D perspective for patients, caregivers, clinical researchers, clinicians and concerned citizens, *European Neuropsychopharmacology*, Volume 53, Supplement 1, December 2021, Page S672.
49. Wilcox, C.S. Update on Alzheimer’s Research-Related Global Challenges, Solutions and Evolving Innovations, *Innovations in Clinical Neuroscience*, Fall (October-December) 2022, Vol. 19., No. 10-12, Supplement, 1, S24.
50. Wilcox, C.S. Demystifying the Alzheimer’s Maze, In Plain Language, *Amazon Press*, *Amazon.com*, ISBN 9798375110387, 2023.
51. Wilcox, C.S. Are the Newest Anti-Alzheimer’s Medicines Being Evaluated Under Outdated Pricing Paradigms? *Medical Research Archives*, Vol 12, No 4 (2024): April Issue, <https://esmed.org/MRA/mra/article/view/5360>; doi: <https://doi.org/10.18103/mra.v12i4.5360>.
52. Wilcox, C.S. Is there an anti-brain-health bias when valuing and pricing the new disease-modifying anti-Alzheimer’s treatments? *Neuroscience Applied*, Vol 3, Supplement 2, 2024. <https://doi.org/10.1016/j.nsa.2024.105069>.
53. Wilcox, C.S. In the Wake of the Presidential Election, Advocating for New Bipartisan Research-Patient-Centric Legislation May Bolster Your Belief in the Political Process! *Innovations In Clinical Neuroscience: ICNS*, October-December 2024, Volume 21, No.10-12, Supplement 1.

ABSTRACTS/VIDEOS & ORAL PRESENTATIONS

1. Cohn, J.B. and Wilcox, C.S. “Effect of withdrawing treatment after long-term administration of alprazolam, lorazepam, or placebo in patients with anxiety disorder,” American College of Neuropsychopharmacology, 21st Annual Meeting, San Juan, Puerto Rico, December 15-17, 1982.

2. Cohn, J.B. and Wilcox, C.S. "Praxilene in the Treatment of Senile Dementia," International Symposium on Conservative Therapy of Arterial Occlusive Disease, Bonn, Germany, May 25, 1984.
3. Cohn, J.B. and Wilcox, C.S. "Comparison of fluoxetine, imipramine and placebo in patients with major depressive disorder," Collegium Internationale Neuro-Psychopharmacologicum 14th C.I.N.P. Congress, Florence, Italy, July 19-23, 1984.
4. Cohn, J.B.; Feigenbaum, A.S. and Wilcox, C.S. "An investigation of ORG 2766 in primary degenerative dementia," II International Congress on Psychogeriatric Medicine, Umeå, Sweden, August 30, 1985.
5. Cohn, J.B.; Feigenbaum, A.S. and Wilcox, C.S. "Treatment of Alzheimer's disease with oral analogue of ACTH," IV World Congress of Psychiatry, Philadelphia, Pennsylvania, September 9, 1985.
6. Cohn, J.B. and Wilcox, C.S. "Evaluation of Alzheimer's disease diagnostic criteria," Collegium Internationale Neuro-Psychopharmacologicum, 15th C.I.N.P. Congress, Puerto Rico, December 16- 20, 1986.
7. Wilcox, C.S.; Hamilton, M.; Cohn, J.B. and Addis, B. The Hamilton Depression Rating Scale: A training film for the assessment of depressed patients. University of California at Los Angeles, Behavioral Sciences Media Laboratory, April 14, 1987.
8. Wilcox, C.S.; Hamilton, M.; Cohn, J.B. and Addis, B. The Hamilton Anxiety Rating Scale: A training film for the assessment of anxious patients. University of California at Los Angeles, Behavioral Sciences Media Laboratory, April 15, 1987.
9. Wilcox, C.S.; Cohn, J.B. and Pyke, R.E. "A six-week, double-blind comparison of adinazolam mesylate and placebo in depressed outpatients," Xth International Congress of Pharmacology, Sydney, Australia, August 27, 1987.
10. Cohn, J.B.; Crowder, J.E.; Wilcox, C.S. and Ryan, P.J. "A placebo- and imipramine-controlled study of paroxetine," 29th Annual NCDEU Meeting, Key Biscayne, Florida, June 2, 1989.
11. Cohn, J.B.; Wilcox, C.S. and Lerer, B.E. "Development of an Early Detection Battery for Dementia of the Alzheimer's Type," American College of Neuropsychopharmacology, Maui, Hawaii, December 11, 1989.
12. Wilcox, C.S.; Cohn, J.B.; Crowder, J.E. and Ryan, P.J. "Patient Motivation and Placebo Response," Associates of Clinical Pharmacology, Annual Meeting, Montreal, Quebec, Canada, May 9, 1990.
13. Cohn, J.B. and Wilcox, C.S. "From Delirium to Dementia," 17th Collegium Internationale Neuro-Psychopharmacologicum, Kyoto, Japan, September 14, 1990.

14. Cohn, J.B.; Wilcox, C.S.; Crowder, J.E.; Guarino, J.J. and Ryan, P.J. "A Controlled Study of Mianserin in Moderately to Severely Depressed Outpatients," American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 10, 1990.
15. Wilcox, C.S.; Cohn, J.B.; Linden, R.D.; Heiser, J.F. and Lucas, P.B. "Predictors of Placebo Response: A Retrospective Analysis," 31st Annual NCDEU Meeting, Key Biscayne, Florida, May 30, 1991.
16. Wilcox, C.S.; Ryan, P.J.; Cohn, J.B.; Morrissey, J.M.; Linden, R.D. and Heiser, J.F. "A Fixed-Dose Study of Adinazolam-SR Tablets in Generalized Anxiety Disorder: A Preliminary Report," 30th Annual A.C.N.P. Meeting, San Juan, Puerto Rico, December 9-12, 1991.
17. Wilcox, C.S.; Cohn, J.B.; Katz, B.B.; Mijares, C.P.; DeFrancisco, D.; Heiser, J.F. and Linden, R.D. "A Placebo-Controlled Study of Two Arylpiperazines in Outpatients with Generalized Anxiety Disorder (GAD)," 31st Annual Meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 15, 1992.
18. Wilcox, C.S. "Drug Development in the 1990s: Bringing New Drugs to Market in the United States," California State University, Los Angeles, CME Guest Speaker, Los Angeles, California, May 5, 1993.
19. Linden, R.D.; Wilcox, C.S.; Heiser, J.F.; Cavanaugh, E.; and Wisselink, P.G. "Are S.S.R.I.s Well Tolerated in Somatizing Depressives?" 33rd Annual NCDEU Meeting, Boca Raton, Florida, June 2, 1993.
20. Wilcox, C.S.; Heiser, J.F.; Cohn, J.B.; Dale, J.L.; Linden, R.D.; Katz, B.B.; Morrissey, J.L. and DeFrancisco, D.F. "Placebo Response in G.A.D. Trials: An Analysis of Purported Predictors," 32nd Annual Meeting, American College of Neuropsychopharmacology, Honolulu, Hawaii, December 14, 1993.
21. Wilcox, C.S.; Wesnes, K.A.; Wisselink, P.G.; Simpson, P.M.; Morrissey, J.L. and Happy, J.M. "A Double-Blind, Single-Dose, Four-Way Crossover Comparison of the Effects of Abecarnil, Alprazolam and Placebo in the Evaluation of Cognitive Function in Male Volunteers," 33rd Annual Meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 13, 1994.
22. Wilcox, C.S. "Alzheimer's Research Update: Midway in the 1990's," Co-sponsored by the Los Angeles Alzheimer's Association and the City of Whittier, Whittier, California, May 4, 1995.
23. Wilcox, C.S.; Cohn, J.B.; Ferguson, J.M.; Dale, J.L. and Fabre, L.F. "A Double-Blind Multicenter Trial of a Low Dose Range and High Dose Range of Gepirone-Extended Release Compared to Placebo in the Treatment of Depressed Outpatients," 35th Annual N.C.D.E.U. Meeting, Orlando, Florida, June 1, 1995.

24. Wilcox, C.S.; Katz, B.B.; Morgan, D.L.; Morrissey, J.L. and Schneider, A.L. "Research Patient Recruitment in the 1990's: The Impacts of Managed Care and Increasing Ethnic Diversity," 35th Annual N.C.D.E.U. Meeting, Orlando, Florida, June 2, 1995.
25. Wilcox, C.S.; Heiser, J.F.; Morrissey, J.L.; Linden, R.D. and Schneider, A.L. "Identification of the 'Reward Gene' as a Predictor in Studies of Obesity and Smoking Cessation," 34th Annual Meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 11, 1995.
26. Wilcox, C.S.; Heiser, J.F.; Morrissey, J.L.; Wisselink, P.G. and Herzog, T. "The D₂ Dopamine Receptor and Obesity Drug Trials: the Genetic "Reward" Link," IBC's Second Annual International Symposium on Obesity, Washington, D.C., March 4-6, 1996.
27. Feiger, A.D.; Bielski, R.D.; Bremner, J.; Heiser, J.F.; Trivedi, M. and Wilcox, C.S. "Efficacy of Nefazodone in Continuation Treatment of Depression," 149th Annual American Psychiatric Association Meeting, New York City, New York, May 7, 1996.
28. Wilcox, C.S.; Dale, J.L.; Katz, B.B.; Mijares, C.P.; Morgan, D.L.; Morrissey, J.L.; Wassom, N.J. and Heiser, J.F. "An Enhanced Methodology and Study Design for Studies of Smoking Cessation," 20th Annual Associates of Clinical Pharmacology Convention, Nashville, Tennessee, May 11-15, 1996.
29. Wilcox, C.S.; Wesnes, K.A.; Heiser, J.F.; Simpson, P.M.; Katz, B.B.; Bianca, R. and Happy, J.M. "A Double-Blind, Eight-Way Crossover Comparison of Abecarnil, Lorazepam and Placebo, Alone and After a Single Dose of Alcohol, on Psychometric Performance in Healthy Volunteers," 36th Annual N.C.D.E.U. Meeting, Boca Raton, Florida, May 29, 1996.
30. Feiger, A.D.; Bielski, R.D.; Bremner, J.; Heiser, J.F.; Trivedi, M. and Wilcox, C.S. "Efficacy of Nefazodone in Continuation Treatment of Depression," 36th Annual N.C.D.E.U. Meeting, Boca Raton, Florida, May 29, 1996.
31. Feiger, A.D.; Kiev, A.; Shrivastava, R.K.; Wisselink, P.G. and Wilcox, C.S. "Nefazodone versus Sertraline in Outpatients with Major Depression: Focus on Efficacy, Tolerability and Effects on Sexual Function and Satisfaction," 36th Annual N.C.D.E.U. Meeting, Boca Raton, Florida, May 30, 1996.
32. Wilcox, C.S.; Heiser, J.F.; Morrissey, J.L.; Katz, B.B.; Linden, R.D. and Schneider, A.L. "A State-of-the-Art Clinical Study Design for Evaluating Potential Treatments of Consumptive Disorders," 32nd Annual Drug Information Association Meeting, San Diego, California, June 11, 1996.
33. Wilcox, C.S.; Morrissey, J.L.; Heiser, J.F.; Dale, J.L.; Katz, B.B. and Schneider, A.L. "Recruitment of Migraineurs for Clinical Trials: Insights on Rapid Patient Enrollment *with* Retention," IBC's International Conference on Advances in Treatment and Therapeutic Development in Migraine, Boston, Massachusetts, July 25 & 26, 1996.

34. Wilcox, C.S.; Linden, R.D.; D'Amico, M.F.; Schneider, A.L.; Morrissey, J.L. and Heiser, J.F. "The Tolerability of Nefazodone in the Treatment of Adult and Elderly Patients with Mood Disorders," 35th Annual Meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 9, 1996.
35. Wilcox, C.S. "Alzheimer's Disease: Research Updates and Caregiving Resources," Invited Speaker - CalTech Senior Care (Staff and Faculty), Connection Lecture Series at California Institute of Technology, Pasadena, California, January 22, 1997.
36. Wilcox, C.S.; Sambunaris, A. and Sachais, B.A. "Strategies for Successful 'Speedy' Collaboration in Clinical Trials," 33rd Annual Drug Information Association Meeting, Montréal, Québec, Canada, June 25, 1997.
37. Wilcox, C.S.; Morrissey, J.L.; Heiser, J.F.; Katz, B.B.; Schneider, A.L.; Bacon, P.F. and DeFrancisco, D. "Protocol Design and Predictors of Placebo Response: Studies with Antidepressants and Anxiolytics," 36th Annual Meeting, American College of Neuropsychopharmacology, Kamuela, Hawaii, December 10, 1997.
38. Wilcox, C.S.; Linden, R.D.; McQuade, R.; Morrissey, J.L.; D'Amico, M.F.; Schneider, A.L. and Heiser, J.F. "Nefazodone Treatment in Elderly Depressed Patients," 151st Annual American Psychiatric Association Meeting, Toronto, Ontario, Canada, June 2, 1998.
39. Wilcox, C.S.; Dren, A.T.; Branconnier, R.J. and Hockley, J.R. "Marketing in Clinical Research - Finding Studies and Patients," 34th Annual Drug Information Association Meeting, Boston, Massachusetts, June 8, 1998.
40. Wilcox, C.S.; Linden, R.D.; D'Amico, M.F.; McQuade, R.; Schneider, A.L.; Morrissey, J.L. and Heiser, J.F. "Nefazodone in the Treatment of Elderly Patients with Depression," XXIst Collegium Internationale Neuro-Psychopharmacologicum Meeting, Glasgow, Scotland, July 13, 1998.
41. Wilcox, C.S.; Morrissey, J.L.; Heiser J.F.; Katz, B.B.; Cho, F.E.; Grosz, D.E.; Linden, R.D. and DeFrancisco, D.F. "Patients' Motivations as Potential Predictors of Placebo Response: Yesterday and Today," 37th Annual Meeting, American College of Neuropsychopharmacology, Las Croabas, Puerto Rico, December 14, 1998.
42. Wilcox, C.S.; Cho, F.E.; Heiser, J.F.; Morrissey, J.L.; Katz, B.B.; Grosz, D.E. and DeFrancisco, D.F. "Placebo Response in Depression Studies: Do Previously Reported Predictors Have Any Utility?" 39th Annual N.C.D.E.U. Meeting, Boca Raton, Florida, June 2, 1999.
43. Thase, M.E.; Ferguson, J.M. and Wilcox, C.S. "Citalopram Treatment of Paroxetine Intolerant Patients," 39th Annual N.C.D.E.U. Meeting, Boca Raton, Florida, June 3, 1999.
44. Stahl, S.M. and Wilcox, C.S. "Placebo-Controlled Comparison of Citalopram and Sertraline in the Treatment of Anxiety Symptoms in Depressed Patients," 39th Annual N.C.D.E.U. Meeting, Boca Raton, Florida, June 3, 1999.

45. Thase, M.E.; Ferguson, J.M. and Wilcox, C.S. "Efficacy and Safety of Citalopram in Paroxetine Intolerant Patients," Annual Meeting of the American Psychiatric Association Institute on Psychiatric Services, New Orleans, Louisiana, November 1, 1999.
46. Wilcox, C.S.; Morrissey, J.L.; Heiser, J.F.; Katz, B.B.; Schneider, A.L.; Delaney, J.E. and Grosz, D.E. "Profiling Migraineurs as Research Subjects: Pharmacoeconomic and Quality of Life Measures," 38th Annual American College of Neuropsychopharmacology (A.C.N.P.) Meeting, Acapulco, Mexico, December 14, 1999.
47. Wilcox, C.S.; Morrissey, J.L.; Heiser, J.F.; Cho, F.E.; Katz, B.B.; Mijares, C.P. and Grosz, D.E. "Major Depressive Disorders and Migraine Headaches: Is Comorbidity a Serious Threat to Homogeneity?" 40th Annual N.C.D.E.U. Meeting, Boca Raton, Florida, May 31, 2000.
48. Wilcox, C.S. "Alzheimer's Disease Research Update," invited speaker for City of Norwalk Continuing Education Seminar, Norwalk, California, August 17, 2000.
49. Wilcox, C.S. "Y2K: Medication and Current Research," L.A. Alzheimer's Association and Kiwanis Club of Van Nuys, Van Nuys, California, August 24, 2000.
50. Wilcox, C.S.; Morrissey, J.L.; Cho, F.E.; Heiser, J.F.; Katz, B.B.; Janko, S.E.; Grosz, D.E. and DeFrancisco, D.F. "Profiling Social Anxiety Disorder Research Subjects: An Evaluation of Symptom Severity, Quality of Life and Overall Representativeness," 39th Annual American College of Neuropsychopharmacology (A.C.N.P.) Meeting, San Juan, Puerto Rico, December 11, 2000.
51. Rapaport, M.H.; Londborg, P.; Heiser, J.F.; Wilcox, C.S.; Bartlett, C.L. and Schwartz, G. "Augmentation with Selective NRI Reboxetine Among Partial Responders to SSRI Therapy: Preliminary Report," 41st Annual N.C.D.E.U. Meeting, Phoenix, Arizona, May 29, 2001.
52. Wilcox, C.S.; Morrissey, J.L.; Cho, F.E.; Grosz, D.E.; Katz, B.B.; Janko, S.E.; Puppione, A.A. and Heiser, J.F. "The Effects of Gender and Methodology on Homogeneity and Outcomes in Clinical Trials: A Look at Social Anxiety Disorder Research Volunteers," 41st Annual N.C.D.E.U. Meeting, Phoenix, Arizona, May 30, 2001.
53. Grosz, D.E.; Morrissey, J.L. and Wilcox, C.S. "Almotriptan is Effective for Multiple Migraine Attacks," 10th International Headache Congress, New York, New York, June 30, 2001.
54. Thase, M.E. and Wilcox, C.S. "The Efficacy of Citalopram in the Treatment of Patients Who Failed Treatment with Fluoxetine or Paroxetine," accepted for presentation at the 14th European College of Neuropsychopharmacology (E.C.N.P.) Congress, Istanbul, Turkey, October 13-17, 2001.

55. Wilcox, C.S.; Heiser, J.F.; Morrissey, J.L.; Grosz, D.E.; Cho, F.E.; Katz, B.B.; Janko, S.E. and Linden, R.D. "Protocol Design and Predictors of Placebo Response in Anxiety Disorders: Generalized Anxiety Disorder vs. Social Anxiety Disorder," 40th Annual American College of Neuropsychopharmacology (A.C.N.P.) Meeting, Waikoloa, Hawaii, December 10, 2001.
56. Wilcox, C.S.; Heiser, J.F.; Rapaport, M.H.; Londborg, P.D. and Schwartz, G.E. "Reboxetine Augmentation of Fluoxetine for Patients with Major Depressive Disorder: An 8-Week Open-Label Study," 42nd Annual NCDEU Meeting, Boca Raton, Florida, June 11, 2002.
57. Wilcox, C.S.; Heiser, J.F.; Rapaport, M.H.; Londborg, P. and Schwartz, G. "Reboxetine Augmentation of Fluoxetine for Patients with Major Depressive Disorder: An 8-Week Open-Label Study," European College of Neuropsychopharmacology (E.C.N.P.) Congress, Barcelona, Spain, October 6, 2002.
58. Wilcox, C.S.; Morrissey, J.L.; Heiser, J.F.; Cho, F.E.; Grosz, D.E.; Katz, B.B. and DeFrancisco, D.F. "Venlafaxine-ER vs. Placebo in Adults with Generalized Social Anxiety Disorder," 41st Annual American College of Neuropsychopharmacology (A.C.N.P.) Meeting, San Juan, Puerto Rico, December 11, 2002.
59. Wilcox, C.S.; Morrissey, J.L.; Cho, F.E.; Heiser, J.F.; Katz, B.B.; Grosz, D.E.; Tong, M. and DeFrancisco, D. "Placebo Response and Social Anxiety Disorder: 'What Happened to Reliable Predictors?'," 43rd Annual NCDEU Meeting, Boca Raton, Florida, May 28, 2003.
60. Wilcox, C.S.; Katz, B.B.; Heiser, J.F.; Cho, F.E.; Morrissey, J.L.; Grosz, D.E.; Hardy, A.I. and DeFrancisco, D.F. "Placebo Response and Anxiety Disorders: A Critical Evaluation of Influential Variables," 16th European College of Neuropsychopharmacology (E.C.N.P.) Congress, Prague, Czech Republic, September 23, 2003.
61. Wilcox, C.S.; Katz, B.B.; Heiser, J.F.; Hardy, A.I.; Cho, F.E.; Adkins, D.M.; Morrissey, J.L. and Grosz, D.E. "Profiling Smoking Cessation Research Subjects: Demographic and Baseline Characteristics as Predictors of Retention/Completion," 42nd Annual American College of Neuropsychopharmacology (A.C.N.P.) Meeting, San Juan, Puerto Rico, December 9, 2003.
62. Wilcox, C.S.; Morrissey, J.L.; Hardy, A.I.; Heiser, J.F.; Katz, B.B.; Adkins, D.M.; Tong, M. and Grosz, D.E. "Predictors of Success in Smoking Cessation Studies: An Analysis of Socioeconomic, Behavioral and Demographic Variables," 43rd Annual American College of Neuropsychopharmacology (A.C.N.P.) Meeting, San Juan, Puerto Rico, December 15, 2004.
63. Wilcox, C.S.; Heiser, J.F.; Katz, B.B.; Thach, A.L.; Henry, M.M.; Cooper, M.E.; Oskooilar, N.; Morrissey, J.L. and Grosz, D.E. "Behavioral, Demographic and Socioeconomic Variables as Potential Predictors of Successful Smoking Cessation, Vis-à-Vis a Clinical Trial," 11th Annual Society for Research on Nicotine and Tobacco (S.R.N.T.) Meeting [and Joint 7th Annual SRNT European Conference], Prague, The Czech Republic, March 21, 2005.

64. Wilcox, C.S.; Oskooilar, N.; Katz, B.B.; Grosz, D.E.; Morrissey, J.L.; Henry, M.M. and De Francisco, D.F. "Pharmacogenomics from the Atypical Depression Study Participants' Perspective," 46th Annual NCDEU Meeting, Boca Raton, Florida, June 14, 2006.
65. Wilcox, C.S.; Heiser, J.F.; Katz, B.B.; Oskooilar, N.; Henry, M.M.; Grosz, D.E.; Morrissey, J.L.; Noble, E.P. and De Francisco, D.F. "A Double-Blind Study Comparing Varenicline with Bupropion-SR and Placebo for Smoking Cessation: Results from a Single Center," 45th Annual American College of Neuropsychopharmacology (A.C.N.P.) Meeting, Hollywood, Florida, December 4, 2006.
66. Wilcox, C.S.; Morrissey, J.L.; Grosz, D.E.; Heiser, J.F.; Henry, M.M.; Oskooilar, N.; Katz, B.B. and De Francisco, D.F. "Are Adult Attention-Deficit Hyperactivity Disorder Research Subjects Representative of the Adult Attention-Deficit Hyperactivity Disorder Population at Large?" 46th Annual American College of Neuropsychopharmacology (A.C.N.P.) Meeting, Boca Raton, Florida, December 10, 2007.
67. Wilcox, C.S.; Oskooilar, N.; Tong, M.; Grosz, D.E.; Morrissey, J.L.; Katz, B.B.; Henry, M.M. and De Francisco, D.F. "Do Depressed Obese Research Patients Respond Differently to Antidepressant Treatment When Compared with Non-Obese Depressed Patients?" 48th Annual NCDEU Meeting, Phoenix, Arizona, May 29, 2008.
68. Wilcox, C.S.; Oskooilar, N.; Katz, B.B.; Henry, M.M.; Tong, M.; Grosz, D.E.; Morrissey, J.L. and De Francisco, D.F. "A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Vilazodone in Patients with Major Depressive Disorder: Results from a Single Center" 47th Annual American College of Neuropsychopharmacology (A.C.N.P.) Meeting, Scottsdale, Arizona, December 10, 2008.
69. Dunayevich, E.; Erickson, J.; Oskooilar, N.; Billes, S.J. and Wilcox, C.S. "Naltrexone SR/Bupropion SR Combination for Smoking Cessation and Prevention of Associated Weight Gain in Overweight and Obese Subjects," 162nd Annual American Psychiatric Association Meeting, San Francisco, California, May 20, 2009.
70. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Henry, M.M.; Grosz, D.E.; Katz, B.B. and De Francisco, D.F. "Transforming Patient Recruitment and Retention Strategies for CNS Clinical Trials: Today's Patient Perspective on the Transactional Model," 49th Annual NCDEU Meeting, Hollywood, Florida, July 1, 2009.
71. Wilcox, C.S.; Noble, E.P.; Ritchie, T.; Oskooilar, N.; Katz, B.B.; Grosz, D.E.; Henry, M.M.; Morrissey, J.L. and De Francisco, D.F. "Integrating Pharmacogenomics in Drug Development: A Preliminary Report on a Study of the Molecular Genetic (DRD2) Basis of Nicotine Addiction and Treatment Response in Cigarette Smokers," 48th Annual American College of Neuropsychopharmacology (A.C.N.P.) Meeting, Hollywood, Florida, December 9, 2009.
72. Wilcox, C.S.; Noble, E.P.; Oskooilar, N.; Henry, M.M.; Ritchie, T. L.; Grosz, D.E.; Katz, B.B. and Heiser, J.F. "Biomarkers and Expediting Drug Development: An Interim Report on the Molecular Genetic (DRD2) Basis of Nicotine Addiction and Treatment Response," 50th Annual NCDEU Meeting, Boca Raton, Florida, June 16, 2010.

73. Harris-Collazo, R.; Wilcox, C.; Erickson, J., Billes, S.K.; Kim, D. and Dunayevich, E. "An Open-Label Study of Naltrexone SR/Bupropion SR Combination Therapy for Smoking Cessation in Overweight and Obese Subjects," 11th International Congress on Obesity, Stockholm, Sweden, July 11-15, 2010.
74. Wilcox, C.S.; Oskooilar, N.; Katz, B.B.; Grosz, D.E.; Tong, M.; Morrissey, J.L.; Henry, M.M. and De Francisco, D.F. "A Randomized, Double-Blind, Placebo-Controlled, Pooled Data Single-Site Assessment of the Efficacy and Safety of Vilazodone in Patients with Major Depressive Disorder," 51st Annual NCDEU Meeting, Boca Raton, Florida, June 15, 2011.
75. Wilcox, C.S. "Protocol Complexity at the Site Level: From the Sites' Perspective," CNS Summit Annual Meeting, Boca Raton, Florida, November 18, 2011.
76. Wilcox, C.S.; Oskooilar, N.; Tong, M.; Morrissey, J.L.; De Francisco, D.F.; Henry, M.M. and Grosz, D.E. "Do Current Internet-Based Patient Recruitment Methods Impact Patient Retention and Completion Rates in Depression Studies and Are These Metrics Truly Indicative of Positive Outcomes?" 50th Annual ACNP Meeting, Waikoloa Beach, Hawaii, December 7, 2011.
77. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Grosz, D.E.; Henry, M.M.; Guevarra, K.A. and De Francisco, D.F. "The Impact(s) of Family Psychiatric History on Signal Detection and Placebo-Response: Meta-Analysis," 52nd Annual NCDEU Meeting, Phoenix, Arizona, May 31, 2012.
78. Wilcox, C.S.; Oskooilar, N.; Tong, M.; Morrissey, J.L.; Henry, M.M.; Grosz, D.E. and De Francisco, D.F. "Statistical Analyses in Smoking Cessation Clinical Trials: A Simplified Model Encompassing More Complexity," 14th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT) Europe, Helsinki, Finland, August 31, 2012.
79. Shiovitz, T.M.; Wilcox, C.S.; Gevorgyan, L.; Morrissey, J.L.; Zarrow, M.E. and Shawkat, M.A. "CNS Sites Cooperate to Detect Duplicate Subjects with a Clinical Trial Subject Registry," 3rd Annual CNS Summit Meeting, Boca Raton, Florida, November 16, 2012.
80. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Henry, M.M.; Grosz, D.E. and Tong, M. "The Failed CNS Studies Phenomenon: Is the Final Factor Looking Us Right in the Eye?" 51st Annual ACNP Meeting, Hollywood, Florida, December 5, 2012.
81. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Grosz, D.E.; Litzinger, J.D.; Henry, M.M.; Feldman, C.R. and De Francisco, D.F. "Research Fraud and Failed Clinical Trials via Fictitious Study Participants: Is it an American or an International Problem?" 25th Annual Drug Information Association (DIA) EuroMeeting, Amsterdam, Netherlands, March 3-6, 2013.
82. Shiovitz, T.M.; Manlosa, N.B.; Gevorgyan, L.; Zarrow, M.E. and Wilcox, C.S. "Characteristics of Duplicate Subjects in a Clinical Trial Subject Registry," 53rd Annual NCDEU Meeting, Hollywood, Florida, May 29, 2013.

83. Shiovitz, T.M.; Wilcox, C.S.; Gevorgyan, L.; Mehra, V. and Mangano, T.C. "Using a Subject Registry to Create a Duplicate-Free Corridor for Conducting Clinical Trials," CNS Summit Conference, Boca Raton, Florida, November 15, 2013.
84. Wilcox, C.S. – Panelist. "Stakeholder Collaboration at the Site Level: Improving Clinical Trial Success," CNS Summit Conference, Boca Raton, Florida, November 16, 2013.
85. Wilcox, C.S.; Morrissey, J.L.; Oskooilar, N.; Henry, M.M.; Grosz, D.E.; Tong, M. and De Francisco, D.F. "Protocol Complexity and Enrollment Eligibility Exclusivity: Are Today's Depression Study Volunteers Truly Representative?" 52nd Annual ACNP Meeting, Hollywood, Florida, December 10, 2013.
86. Wilcox, C.S. and Lucariello, V.M. "Hidden Costs for Sites and Sponsors: What costs are not in study budgets but not 'the cost of doing business'?" MAGI's Clinical Research Conference – 2014 East, Philadelphia, Pennsylvania, May 5, 2014.
87. Romano, S.; Jovic, S.; Burch, D. and Wilcox, C.S. "Real Time: CNS Edition – A Candid and Interactive Session," moderated by Amir Kalali, M.D. – 5th Annual CNS Summit Conference, Boca Raton, Florida, November 15, 2014.
88. Wilcox, C.S.; Oskooilar, N.; Guevarra, K.A.; Tong, M.; Morrissey, J.L.; Grosz, D.E. and De Francisco, D.F. "Preliminary Report: Does a 'Reduce-to-Quit' Smoking Cessation Strategy Increase or Decrease Success?" 15th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT) Europe, Santiago de Compostela – Galicia, Spain, September 20, 2014.
89. Wilcox, C.S.; Oskooilar, N.; Guevarra, K.A.; Tong, M.; Morrissey, J.L.; Grosz, D.E. and De Francisco, D.F. "Smoking Cessation Through Reduction: Does It Enhance Or Diminish Successful Quitting?" 53rd Annual ACNP Meeting, Phoenix, Arizona, December 9, 2014.
90. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Tong, M.; Grosz, D.E.; Guevarra, K.A.; Feldman, C.R. and De Francisco, D.F. "The Efficacy of Varenicline Compared to Placebo for Smoking Cessation Using a Reduce-to-Quit Strategy: One Research Center's Results" 21st Annual SRNT Meeting, Philadelphia, Pennsylvania, February 26, 2015.
91. Wilcox, C.S.; Oskooilar, N.; Guevarra, K.A.; Tong, M.; Grosz, D.E.; Morrissey, J.L.; Henry, M.M. and De Francisco, D.F. "A Double-Blind, Active- and Placebo-Controlled Evaluation of the Neuropsychiatric Safety and Efficacy of Varenicline and Bupropion for Smoking Cessation in Subjects with (Pre-Existing) Psychiatric Disorders: An Objective Blinded Analysis" 54th Annual ACNP Meeting, Hollywood, Florida, December 7, 2015.
92. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; De Francisco, D.F.; Guevarra, K.A.; Grosz, D.E.; Henry, M.M.; Litzinger, J.D. and Tong, M. "Smoking Cessation in Patients with a Prior or Current Psychiatric Disorder: A Double-Blind Comparative Analysis of the Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, Nicotine Replacement Therapy [NRT] and Placebo" 22nd Annual Meeting of the Society for Research on Nicotine and Tobacco, Chicago, Illinois, March 3, 2016.

93. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Rosenberg, D.; Tong, M.; Henry, M.; Badgett, L. and Grosz, D. “Could a Paradigm Shift in Consumptive Disorders Research Benefit Patients and Sponsors Alike? A Smoking Cessation Case Study Reinforces → The Manner in Which We Look at Things, Determines What We See!” CNS Summit 2016, Boca Raton, Florida, October 28, 2016.
94. Wilcox, C.S.; Tong, M.; Oskooilar, N.; Morrissey, J.L.; De Francisco, D.; Henry, M.; Badgett, L. and Grosz, D. “A 12-Week, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Phase-2, Dose Selection Study of Lorcaserin Hydrochloride for Smoking Cessation: Preliminary Report,” 55th Annual ACNP Meeting, Hollywood, Florida, December 7, 2016.
95. Wilcox, C.S.; Oskooilar, N.; Tong, M.; Grosz, D.; Henry, M.; Morrissey, J.; Washington, J. and De Francisco, D. “A Double-Blind, Randomized, Placebo-Controlled, Phase-2, Dose Selection Study of Lorcaserin Hydrochloride for Smoking Cessation: Different Analyses Produce Markedly Different Results,” Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting, Florence, Italy, March 9, 2017.
96. Wilcox, C.S.; Grosz, D.E.; Tong, M.; Rosenberg, D.A.; Morrissey, J.L.; De Francisco, D.F.; Feldman, C.R.; Henry, M.M.; Badgett, L.M. and Oskooilar, N. “Serving the Needs of Our Increasingly Diverse Population: It All Begins with Recruitment!” ASCP Annual Meeting, Miami Beach, Florida, June 1, 2017.
97. Harrison, J.; Wilcox, C.; Carrillo, M.; Pendergrass, C.; Gold, M. and Holt, B. Panel Session: “Revolutionizing Outcome Measures in Alzheimer’s Trials” CNS Summit 2017, Boca Raton, Florida, November 17, 2017.
98. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Rosenberg, D.A.; Tong, M.; Henry, M.M. and Grosz, D.E. “Successful Lifespan-Targeted Patient Recruitment Strategies for Outpatient Psychiatric and Neurological Clinical Trials,” ASCP Annual Meeting, Miami, Florida, May 30, 2018.
99. Malhotra, S.; Wise-Rankovic, A.; Wilcox, C.S.; Metcalfe, J.; Mitsi, G.; Boyer, S.; Webster, I. and Grom, T. “Women in Leadership: Enhancing Success and Culture Life Series,” 9th Annual CNS Summit Conference, Boca Raton, Florida, November 1, 2018.
100. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Rosenberg, D.A.; Tong, M.; Henry, M.M. and Grosz, D.E. “Innovations in Personalized Medicine: A Pilot Study Looking at the Potential vs. the Promise in Major Depressive Disorder,” ASCP Annual Meeting, Scottsdale, Arizona, May 29, 2019.
101. Wilcox, C.S.; Verghese, C.; Simmons, A. and Franceschi, L.M.K. “Layperson/Plain Language Summaries: Can Sponsors, CROs and Sites Deliver by 2020?” 10th Annual CNS Summit Conference, Boca Raton, Florida, November 1, 2019.
102. Wilcox, C.S. “Public Image and Sentiment Toward the Pharmaceutical Industry: What Can We Do to Reverse the Negative Trend? ASCP Annual Meeting, Virtual Conference, May 29, 2020.

103. Wilcox, C.S. “Alzheimer’s #115: A Global 3-D Perspective for Patients, Caregivers, Clinical Researchers, Clinicians and Concerned Citizens,” 34th Annual ECNP Congress, Lisbon, Portugal, October 4, 2021.
104. Malhotra, S.; Wise, A.; Wilcox, C.; Versavel, S.; Whitmore, S. and Mitchell, Z. “Achieving Diversity in Clinical Trials: Overcoming Industry Challenges to Develop Actionable Plans for Implementation,” Spotlight Session Panel Presentation and Discussion, 12th Annual CNS Summit Conference, Boston, Massachusetts, November 8, 2021.
105. Wilcox, C.S. “Diversity, Equity and Inclusion: Alzheimer’s and Dementia Research-Related Global Challenges, Solutions and Opportunities,” 12th Annual CNS Summit Conference, Boston, Massachusetts, November 9, 2021.
106. Malhotra, S.; Wise, A.; Wilcox, C. and Versavel, S. “Achieving Diversity in Clinical Trials,” Panel Session, ASCP Annual Meeting, Scottsdale, Arizona, June 2, 2022.
107. Wilcox, C.S. Panel Session: Achieving Diversity in Clinical Trials, “Diversity, Equity and Inclusion: Globalized Insights for Localized Strategies,” ASCP Annual Meeting, Scottsdale, Arizona, June 2, 2022.
108. Wilcox, C.S. “Value-Based Pricing of an Efficacious Anti-Alzheimer’s Treatment: Disease-Modifying or Symptomatic Relief, More than a \$56,000 Question,” 35th ECNP Congress, Vienna, Austria, October 16, 2022.
109. Wilcox, C.S. “Update on Alzheimer’s Research-Related Global Challenges, Solutions and Evolving Innovations.” 13th Annual CNS Summit, Boca Raton, Florida, November 19, 2022.
110. Wilcox, C.S. and Mahableshwarkar, A. Investigator-Industry Collaboration Session “How to Pursue Industry Funding for Investigator-Initiated Trials,” ASCP Annual Meeting, Miami Beach, Florida, June 1, 2023.
111. Wilcox, C.S. “Equitable Pricing of a Novel Anti-Alzheimer’s Therapeutic: Your Viewpoint Determines Your View,” ASCP Annual Meeting, Miami Beach, Florida, June 1, 2023.
112. Wilcox, C.S. “Are Current International Pricing Paradigms for an Efficacious Disease-Modifying Anti-Alzheimer’s Treatment Equitable? Are Quality-Adjusted Life-Years Worth Considering?” Alzheimer’s Association International Conference, Amsterdam, Netherlands, July 18, 2023.
113. Wilcox, C.S., Chairman; Lee, E.; Lao, Y. and Azizi, T. World Brain Disorders and Neuroscience Summit, Hybrid Session, Alzheimer’s and Neurodegenerative Diseases, Singapore, November 9, 2023.
114. Wilcox, C.S. “Layperson/Plain Language Summaries: Can Sponsors, CROs and Sites Deliver in 2024? Update 2023,” World Brain Disorders and Neuroscience Summit, Singapore, November 9, 2023.

115. Wilcox, C.S., Keynote Speaker/Presenter, “New Advances in Alzheimer’s Treatments,” California State University at Fullerton, Osher Lifelong Learning Institute, Fullerton, California, May 10, 2024.
116. Wilcox, C.S. “Layperson/Plain Language Summaries: Global Challenges and Opportunities in 2024,” ASCP Annual Meeting, Miami, Florida, May 29, 2024.
117. Wilcox, C.S. “Investigator-Industry Collaboration Session,” Sub-group: Investigator-Initiated Studies, Co-Panelist/Discussant, ASCP Annual Meeting, Miami, Florida, May 30, 2024.
118. Wilcox, C.S. “Is there an anti-brain-health bias when valuing and pricing the new disease-modifying anti-Alzheimer’s treatments?” 37th ECNP Congress, Milan, Italy, September 24, 2024.
119. Wilcox, C.S. “In the Wake of the Presidential Election, Advocating for New Bi-Partisan Research-Patient-Centric Legislation may Bolster Your Belief in the Political Process!” 15th Annual CNS Summit, Boston, Massachusetts, November 12, 2024.
120. Wilcox, C.S., Chairman; Prasad, K.N.; Zhang, J. and Li, X. World Brain Disorders and Neuroscience Summit, Hybrid Session, Alzheimer’s Disease and Dementia, Kyoto, Japan, March 28, 2025.
121. Wilcox, C.S. “Will the Recent Regulatory Approval(s) of the New Disease-Modifying Treatments for Alzheimer’s Spark an Uptick in Additional AD-Related Clinical Research?” World Brain Disorders and Neuroscience Summit (BDNS), Kyoto, Japan, March 28, 2025.

SELECTED SPECIALIZED TRAINING - *Available Upon Request*